Hvis et prøveresultat tyder på mulig kardiel skade i forbindelse med Caelyx behandling, skal fordelen ved fortsat terapi nøje vurderes over for risikoen for kardiel skade.
If a test result indicates possible cardiac injury associated with Caelyx therapy, the benefit of continued therapy must be carefully weighed against the risk of myocardial injury.